ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give ImmunityBio a consensus "Moderate Buy" rating (five buys, one sell) with an average 12‑month price target of $11.80, and several firms recently raised targets (e.g., HC Wainwright to $10, Jefferies to $9, Piper Sandler to $7, D. Boral to $24).
• Company insiders have sold 226,967 shares (~$1.53M) over the past three months—even though insiders still own a controlling 69.48% of the company’s stock.
• Shares opened at $6.25 (up ~5.8%), market cap ~$6.16B, 1‑year range $1.83–$8.28; the latest quarter slightly beat EPS and revenue estimates, while sell‑side consensus expects about −0.92 EPS for the current year.

Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $11.80.

A number of equities analysts have recently commented on the stock. Piper Sandler raised their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an "overweight" rating in a report on Tuesday, January 20th. HC Wainwright raised their price target on shares of ImmunityBio from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of ImmunityBio in a report on Monday, December 29th. D. Boral Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of ImmunityBio in a research note on Tuesday, January 20th. Finally, Jefferies Financial Group raised their target price on ImmunityBio from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Friday, December 12th.

Insiders Place Their Bets

In other news, Director Barry J. Simon sold 151,967 shares of the business's stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the sale, the director owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christobel Selecky sold 50,000 shares of the company's stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $5.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 226,967 shares of company stock valued at $1,531,912. Company insiders own 69.48% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Slow Capital Inc. bought a new stake in ImmunityBio during the 3rd quarter worth approximately $25,000. Truist Financial Corp acquired a new position in ImmunityBio in the third quarter worth $27,000. Swiss Life Asset Management Ltd bought a new stake in shares of ImmunityBio during the third quarter worth $27,000. Diversify Advisory Services LLC acquired a new stake in shares of ImmunityBio in the second quarter valued at $27,000. Finally, Summit X LLC bought a new position in shares of ImmunityBio in the second quarter valued at about $28,000. Institutional investors own 8.58% of the company's stock.

ImmunityBio Trading Up 5.8%

Shares of NASDAQ:IBRX opened at $6.25 on Friday. The firm has a market capitalization of $6.16 billion, a PE ratio of -15.24 and a beta of 0.03. ImmunityBio has a 1-year low of $1.83 and a 1-year high of $8.28. The business's 50 day moving average is $3.14 and its 200-day moving average is $2.69.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.06 million during the quarter, compared to the consensus estimate of $31.88 million. On average, sell-side analysts predict that ImmunityBio will post -0.92 EPS for the current year.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.